中信证券助力映恩生物完成2022年以来最大规模港股18A IPO

Group 1 - The core viewpoint of the news is that Emon Biologics successfully completed its IPO on the Hong Kong Stock Exchange, raising a total of $242 million, marking it as the largest biotech IPO in Hong Kong since 2022 [1][4] - Emon Biologics focuses on the research and development of antibody-drug conjugates (ADCs) for cancer and autoimmune diseases, with a pipeline of 12 self-developed ADC candidates [3][6] - The company has established multiple overseas licensing collaborations with major pharmaceutical companies, with a total transaction value exceeding $6 billion [3] Group 2 - The IPO is noted as the largest 18A IPO project in Hong Kong since 2022, with significant interest from both domestic and international investors [4] - The offering attracted nearly 100 well-known institutions, with international placements being oversubscribed by more than 14 times, including top sovereign funds and large public and private funds [4] - CITIC Securities played a crucial role in facilitating the IPO, leveraging its international service advantages to support innovative biotech companies in accessing overseas markets [5] Group 3 - Emon Biologics was founded in 2019 and aims to become a global leader in the discovery, development, and commercialization of innovative ADC therapies [6] - The company’s mission is to provide innovative treatment solutions that improve patient outcomes in the field of cancer and autoimmune diseases [6]